SG11201507521UA - Lymphocyte biomarkers for determining the clinical response to therapy with mesenschymal stromal cells(msc) - Google Patents
Lymphocyte biomarkers for determining the clinical response to therapy with mesenschymal stromal cells(msc)Info
- Publication number
- SG11201507521UA SG11201507521UA SG11201507521UA SG11201507521UA SG11201507521UA SG 11201507521U A SG11201507521U A SG 11201507521UA SG 11201507521U A SG11201507521U A SG 11201507521UA SG 11201507521U A SG11201507521U A SG 11201507521UA SG 11201507521U A SG11201507521U A SG 11201507521UA
- Authority
- SG
- Singapore
- Prior art keywords
- mesenschymal
- msc
- therapy
- determining
- stromal cells
- Prior art date
Links
- 239000000090 biomarker Substances 0.000 title 1
- 210000004698 lymphocyte Anatomy 0.000 title 1
- 210000002536 stromal cell Anatomy 0.000 title 1
- 238000002560 therapeutic procedure Methods 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/35—Fat tissue; Adipocytes; Stromal cells; Connective tissues
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/33—Fibroblasts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
- A61K39/4621—Cellular immunotherapy characterized by the effect or the function of the cells immunosuppressive or immunotolerising
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/46433—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56966—Animal cells
- G01N33/56972—White blood cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/26—Universal/off- the- shelf cellular immunotherapy; Allogenic cells or means to avoid rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
- G01N2333/70514—CD4
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
- G01N2333/70517—CD8
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
- G01N2333/70539—MHC-molecules, e.g. HLA-molecules
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Virology (AREA)
- Developmental Biology & Embryology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Urology & Nephrology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Mycology (AREA)
- General Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Transplantation (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13382091 | 2013-03-15 | ||
| PCT/EP2014/055282 WO2014140362A2 (en) | 2013-03-15 | 2014-03-17 | Lymphocyte biomarkers for determining the clinical response to cell therapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201507521UA true SG11201507521UA (en) | 2015-10-29 |
Family
ID=48044710
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201507521UA SG11201507521UA (en) | 2013-03-15 | 2014-03-17 | Lymphocyte biomarkers for determining the clinical response to therapy with mesenschymal stromal cells(msc) |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US10660920B2 (en) |
| EP (2) | EP3581932A1 (en) |
| JP (2) | JP6567430B2 (en) |
| AU (2) | AU2014230014B2 (en) |
| CA (2) | CA3188652A1 (en) |
| DK (1) | DK2972368T3 (en) |
| ES (1) | ES2748825T3 (en) |
| HK (1) | HK1219775A1 (en) |
| HU (1) | HUE046531T2 (en) |
| IL (1) | IL241586B (en) |
| PL (1) | PL2972368T3 (en) |
| PT (1) | PT2972368T (en) |
| SG (1) | SG11201507521UA (en) |
| WO (1) | WO2014140362A2 (en) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060045872A1 (en) | 2004-08-25 | 2006-03-02 | Universidad Autonoma De Madrid Ciudad Universitaria de Cantoblanco | Use of adipose tissue-derived stromal stem cells in treating fistula |
| EP3581932A1 (en) | 2013-03-15 | 2019-12-18 | TiGenix, S.A.U. | Lymphocyte biomarkers for determining the clinical response to cell therapy |
| CA2983950A1 (en) * | 2015-04-24 | 2016-10-27 | Tigenix S.A.U. | Biomarkers for determining the clinical response to cell therapy |
| GB201604304D0 (en) * | 2016-03-14 | 2016-04-27 | Tigenix S A U | Adipose tissue-derived stromal stem cells for use in treating refractory complex perianal fistulas in crohn's disease |
| CN110691600B (en) * | 2016-11-11 | 2024-04-16 | 美商生命科学有限公司 | Method for realizing cell immunity and humoral immunity by using human mesenchymal stem cells |
| BR112021016316A8 (en) * | 2019-02-27 | 2023-04-11 | Tigenix S A U | IN VITRO METHOD FOR SELECTING A STEM CELL (SC) POPULATION, PHARMACEUTICAL COMPOSITION, METHOD FOR PREPARING A PHARMACEUTICAL COMPOSITION, USE OF THE PHARMACEUTICAL COMPOSITION, AND USE OF THE SC POPULATION |
| WO2021207192A1 (en) * | 2020-04-08 | 2021-10-14 | Figene, Llc | Methods and compositions for allergy and asthma treatment using fibroblasts |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE60043511D1 (en) * | 1999-10-20 | 2010-01-21 | Chugai Pharmaceutical Co Ltd | USE OF G-CSF TO INHIBIT GVHD |
| EP2824174B1 (en) * | 2004-03-22 | 2018-11-28 | Mesoblast International Sàrl | Mesenchymal stem cells and uses therefor |
| EP1871419A4 (en) * | 2005-04-22 | 2009-01-14 | Univ Maryland | Methods of treating graft versus host disease |
| EP2694080B1 (en) * | 2011-04-06 | 2018-03-14 | SanBio, Inc. | Methods and compositions for modulating peripheral immune function |
| EP3581932A1 (en) | 2013-03-15 | 2019-12-18 | TiGenix, S.A.U. | Lymphocyte biomarkers for determining the clinical response to cell therapy |
-
2014
- 2014-03-17 EP EP19187915.4A patent/EP3581932A1/en active Pending
- 2014-03-17 PL PL14712628T patent/PL2972368T3/en unknown
- 2014-03-17 JP JP2015562256A patent/JP6567430B2/en active Active
- 2014-03-17 ES ES14712628T patent/ES2748825T3/en active Active
- 2014-03-17 HU HUE14712628A patent/HUE046531T2/en unknown
- 2014-03-17 SG SG11201507521UA patent/SG11201507521UA/en unknown
- 2014-03-17 WO PCT/EP2014/055282 patent/WO2014140362A2/en active Application Filing
- 2014-03-17 DK DK14712628.8T patent/DK2972368T3/en active
- 2014-03-17 CA CA3188652A patent/CA3188652A1/en active Pending
- 2014-03-17 PT PT147126288T patent/PT2972368T/en unknown
- 2014-03-17 AU AU2014230014A patent/AU2014230014B2/en active Active
- 2014-03-17 EP EP14712628.8A patent/EP2972368B1/en active Active
- 2014-03-17 CA CA2906299A patent/CA2906299C/en active Active
- 2014-03-17 US US14/776,233 patent/US10660920B2/en active Active
-
2015
- 2015-09-16 IL IL241586A patent/IL241586B/en active IP Right Grant
-
2016
- 2016-06-30 HK HK16107629.6A patent/HK1219775A1/en unknown
-
2019
- 2019-07-31 JP JP2019140842A patent/JP6883070B2/en active Active
-
2020
- 2020-02-05 AU AU2020200807A patent/AU2020200807B2/en active Active
- 2020-04-21 US US16/854,294 patent/US11478511B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| WO2014140362A2 (en) | 2014-09-18 |
| JP2019215359A (en) | 2019-12-19 |
| WO2014140362A3 (en) | 2015-04-16 |
| US11478511B2 (en) | 2022-10-25 |
| HK1219775A1 (en) | 2017-04-13 |
| HUE046531T2 (en) | 2020-03-30 |
| EP2972368B1 (en) | 2019-07-24 |
| EP2972368A2 (en) | 2016-01-20 |
| US20200261511A1 (en) | 2020-08-20 |
| JP2016516985A (en) | 2016-06-09 |
| CA2906299C (en) | 2023-04-04 |
| CA2906299A1 (en) | 2014-09-18 |
| AU2020200807B2 (en) | 2021-10-28 |
| US20160067285A1 (en) | 2016-03-10 |
| DK2972368T3 (en) | 2019-10-07 |
| JP6567430B2 (en) | 2019-08-28 |
| ES2748825T3 (en) | 2020-03-18 |
| US10660920B2 (en) | 2020-05-26 |
| JP6883070B2 (en) | 2021-06-09 |
| PT2972368T (en) | 2019-10-18 |
| IL241586B (en) | 2019-02-28 |
| AU2014230014A1 (en) | 2015-10-29 |
| EP3581932A1 (en) | 2019-12-18 |
| CA3188652A1 (en) | 2014-09-18 |
| PL2972368T3 (en) | 2020-03-31 |
| AU2020200807A1 (en) | 2020-02-20 |
| AU2014230014B2 (en) | 2019-11-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3010570A4 (en) | Clinical interface | |
| IL241586B (en) | Lymphocyte biomarkers for determining the clinical response to therapy with mesenschymal stromal cells(msc) | |
| EP2872533A4 (en) | Methods of assessing the suitability of transduced t cells for administration | |
| EP2871470A4 (en) | Electrochemical biosensor with improved accuracy | |
| HK1221250A1 (en) | Structure for culturing cells | |
| PL2784454T3 (en) | Weighing cell diagnosis | |
| HK1213830A1 (en) | Biomarkers predictive for clinical response for glatiramer acetate | |
| EP3058347A4 (en) | Photometric measurement cell | |
| EP2975110A4 (en) | Cell culture device | |
| IL245265B (en) | Antibodies specific to fcrn | |
| HUP1200239A2 (en) | Quantitative biomarkers of the erythrocyte membrane | |
| GB2518263B (en) | Diamond based electrochemical sensors | |
| HK1202621A1 (en) | Analyte meter for test strips | |
| DK2951552T3 (en) | REQUIREMENT FOR COLLECTION USE | |
| EP3052943A4 (en) | Biomarkers for cell therapy | |
| HK1250176A1 (en) | Biomarkers for determining the clinical response to cell therapy | |
| GB2517918B (en) | Weighing scale system with interface component | |
| GB201316131D0 (en) | Biomarkers for disease stratification | |
| GB201315532D0 (en) | Methods for detecting proteins | |
| HK1216265A1 (en) | Anti-mif antibody cell migration assay -mif | |
| EP3060917A4 (en) | Assays for macromolecular analytes | |
| EP2957907A4 (en) | METHOD FOR DETECTING c-MET GENE-AMPLIFIED CELL | |
| HUP1300692A2 (en) | Honeycomb connection for hives with improved features | |
| GB201300887D0 (en) | Biodiesel Processor | |
| SG11201508791WA (en) | Melt curve analysis |